Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
This is a single-center phase Ⅱ study designed to evaluated the efficacy and safety of pegylated liposomal doxorubicin（PLD）in combination with trastuzumab in HER-2 positive metastatic breast cancer .
HER2-positive Breast Cancer
DRUG: pegylated liposomal doxorubicin
Objective response rate (ORR), The ORR will be calculated as the proportion of patients in the Efficacy Evaluable Patient Set who achieve complete response (CR) and partial response (PR), approximately 6 months
Progression-free survival (PFS), PFS will be defined as the time from first dose of study drug until documentation of disease progression or death from any cause, approximately 1.5 years|Incidence and Severity of adverse events, approximately 1.5 years
This is a single-center phase Ⅱ study designed to evaluated the efficacy and safety of pegylated liposomal doxorubicin（PLD）in combination with trastuzumab in HER-2 positive metastatic breast cancer .